Evidence map›Paper›PMID 38580534›Full record

ArticleTrends in cancer2024

A big step for MYC-targeted therapies.

Danielle F Atibalentja, Anja Deutzmann, Dean W Felsher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Danielle F AtibalentjaDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Anja DeutzmannDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Dean W FelsherDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Electronic address: dfelsher@stanford.edu.

Funding

Targeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9M
Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular CarcinomaU01CA288433 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, VERNA, ELIZABETH CLARICE · 2023 to 2025
$1.3M
NCI NIH HHS R35 CA253180NCI NIH HHS U01 CA288433
6 · The paper itself

Abstract

The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.

Indexed as

Molecular Targeted TherapyNeoplasmsProto-Oncogene MasProto-Oncogene Proteins c-mycAntineoplastic AgentsClinical Trials, Phase I as TopicGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsProto-Oncogene MasProto-Oncogene Proteins c-myccancerimmunotherapyMYCOMO-103Omomyconcogene addictiontumor

Identifiers

PMID38580534
PMCPMC11574775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.